Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1017711 | 0.81 | CHEK1 (0.56) | CHEK1CHUKMAPK1 | |
| SCHEMBL20182173 | 0.81 | PDK2 (0.45) | CHEK1PDK2PDK4HSP90AA1HSP90AB1 | |
| SCHEMBL19667434 | 0.79 | PDK2 (0.44) | CHEK1PDK2PDK4HSP90AA1HSP90AB1 | |
| SCHEMBL9565767 | 0.78 | CHEK1 (0.37) | CHEK1HSP90AA1HSP90AB1DYRK1AMAPK1 | |
| SCHEMBL10938074 | 0.78 | PDK2 (0.42) | CHEK1PDK2PDK4HSP90AA1HSP90AB1 | |
| SCHEMBL3797321 | 0.78 | CHUK (0.58) | CHEK1CHUK | |
| SCHEMBL13215442 | 0.78 | PDK2 (0.42) | CHEK1PDK2PDK4HSP90AA1HSP90AB1 | |
| SCHEMBL19731488 | 0.77 | CHEK1 (0.49) | CHEK1HSP90AB1CHUKMAPK1CDK9 | |
| SCHEMBL29589353 | 0.77 | CHEK1 (0.49) | CHEK1HSP90AB1CHUKMAPK1CDK9 | |
| SCHEMBL13215451 | 0.74 | PDK2 (0.43) | PDK2PDK4HSP90AA1HSP90AB1CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| US-20250084119-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2025-03-13 | — | — | US | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240207299-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES FOR TREATING OR PREVENTING A SARS-COV-2 INFECTION | CHIMERIX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207299-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES FOR TREATING OR PREVENTING A SARS-COV-2 INFECTION | CHIMERIX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11981700-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | CHIMERIX, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| WO-2023110843-A1 | HETEROBICYCLIC DERIVATIVES AS ITK INHIBITORS | ALMIRALL, S.A. (ES) | 2023-06-22 | — | — | WO | disclosed |
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-12-06 | — | — | US | disclosed |
| US-20170044202-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2017-02-16 | — | — | US | disclosed |
| WO-2017024310-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF USEFUL AS ANTIVIRAL AGENTS | CHIMERIX, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017024310-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF USEFUL AS ANTIVIRAL AGENTS | CHIMERIX, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | PFIZER INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156845-B2 | 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors | PFIZER INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140005183-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors | PFIZER (US) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518764-B2 | Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction | BCL6, BCL6B, BCL3 | CHEK1 1794/4885PDK2 2903/4885PDK4 1924/4885 |
| US-11981700-B2 | Pyrrolopyrimidine nucleosides and analogs thereof | TYMP, PNP, DPYD | CHEK1 1761/4885PDK2 398/4885PDK4 696/4885 |
| US-20230250100-A1 | Pyrrolopyrimidines as CFTR Potentiators | CFTR, P2RX1, P2RX5 | CHEK1 1946/4885PDK2 2433/4885PDK4 1558/4885 |
| US-20150366874-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d]Pyrimidines As LRRK2 Inhibitors | LRRK2, PARK7, BRCA1 | CHEK1 46/4885PDK2 88/4885PDK4 148/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | CHEK1 1951/4885PDK2 3977/4885PDK4 3418/4885 |
| US-20250084119-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, PNP, DPYD | CHEK1 1761/4885PDK2 398/4885PDK4 696/4885 |
| US-20170044202-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES AND ANALOGS THEREOF | TYMP, ITPA, IMPDH1 | CHEK1 1883/4885PDK2 557/4885PDK4 863/4885 |
| US-20140005183-A1 | Novel 4-(Substituted Amino)-7H-Pyrrolo[2,3-d] Pyrimidines As LRRK2 Inhibitors | LRRK2, PARK7, BRCA1 | CHEK1 46/4885PDK2 88/4885PDK4 148/4885 |
| US-20240207299-A1 | PYRROLOPYRIMIDINE NUCLEOSIDES FOR TREATING OR PREVENTING A SARS-COV-2 INFECTION | PNP, ACE2, TYMP | CHEK1 1179/4885PDK2 170/4885PDK4 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.